HCW Biologics's EBIT per Share for the
three
months ended in Mar. 2026 was $4.34.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.01.
During the past 3 years, the average EBIT per Share Growth Rate was 31.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for HCW Biologics's EBIT per Share or its related term are showing as below:
HCWB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -52 Med: -5.9 Max: 31.7
Current: 31.7
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of HCW Biologics was 31.70% per year. The lowest was -52.00% per year. And the median was -5.90% per year.
HCWB's 3-Year EBIT Growth Rate is ranked better than 70.87% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs HCWB: 31.70
HCW Biologics's EBIT for the
three
months ended in Mar. 2026 was $3.93 Mil.
HCW Biologics (NAS:HCWB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
HCW Biologics EBIT per Share Related Terms
HCW Biologics EBIT per Share Historical Data
* Premium members only.
The historical data trend for HCW Biologics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a EBIT per Share of $-11.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #344 out of 1181 companies in the Biotechnology industry, placing it in the top 29.1%.
Is HCW Biologics' EBIT per Share too high?
HCW Biologics' current EBIT per Share is $-11.01. Based on the distribution chart, HCW Biologics ranks #344 out of 1181 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' EBIT per Share compare to KAPA and IMNN?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #344 out of 1181 companies for EBIT per Share. This puts HCW Biologics in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current EBIT per Share is $-11.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $0.88 — trading 88% below its estimated fair value. The current EBIT per Share is $-11.01. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For HCW Biologics (HCWB), the current EBIT per Share is $-11.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $0.88 is trading 88% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
EBIT per Share: $-11.01
GF Value™: $7.29 vs. price of $0.88 (88% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
